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Abstract
 
Recently we have identified a novel protein NIP45 (nuclear factor of activated T cells
[NFAT]-interacting protein) which substantially augments interleukin (IL)-4 gene transcrip-
tion. The provision of NIP45 together with NFAT and the T helper cell type 2 (Th2)-specific
transcription factor c-Maf to cells normally refractory to IL-4 production, such as B cells or
Th1 clones, results in substantial IL-4 secretion to levels that approximate those produced by
primary Th2 cells. In studies designed to further our understanding of NIP45 activity, we have
uncovered a novel facet of IL-4 gene regulation. We present evidence that members of the tu-
mor necrosis factor receptor–associated factor (TRAF) family of proteins, generally known to
function as adapter proteins that transduce signals from the tumor necrosis factor receptor su-
perfamily, contribute to the repression of IL-4 gene transcription and that this effect is medi-
ated through their interaction with NIP45.
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Introduction
 
IL-4, originally identified as a B cell growth factor, has
proven to be a critical and multifunctional modulator of
immune processes (1). As virtually all hematopoietic cells
possess surface receptors for IL-4, this cytokine affects the
function of T cells, B cells, macrophages, dendritic cells,
and mast cells among others. Interestingly, IL-4 itself plays
a key role in the generation and maintenance of IL-4–pro-
ducing cells. CD4
 
 
 
 T cells which classically deliver helper
signals via secreted cytokines can be divided into two
groups based on their different patterns of cytokine pro-
duction: Th1 (IFN-
 
 
 
, TNF-
 
 
 
, and IL-2) and Th2 (IL-4,
IL-5, IL-6, IL-10, and IL-13)
 
 
 
(2, 3). Polarization of CD4
 
 
 
T helper precursor cells (which are functionally naive and
referred to as Thp) to either a Th1 or Th2 dominant popu-
lation is an important determinant of the type of immune
response that is initiated and whether this immune response
is ultimately protective or pathogenic. Th1 cells function to
promote host resistance to many intracellular microbes by
activating macrophages whereas Th2 cells are known to be
important in certain humoral responses such as eradicating
extracellular helminthic parasites and also are critical in al-
lergic responses. The influence from IL-4 on uncommitted
Thp cells is twofold. IL-4 signaling during primary activa-
tion of the Th cell can initiate a program of Th2 develop-
ment and also suppress Th1 development by inhibiting
IFN-
 
 
 
 production (3–5).
The importance of IL-4 is underscored by the physiolog-
ical consequences of its dysregulation. Mice harboring tar-
geted mutations in the IL-4 locus, or the IL-4 signaling
pathway — that is the IL-4 receptor through which IL-4
signaling occurs or a downstream signaling molecule Stat6
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— show marked impairment in Th2 development and di-
minished IgE/IgG1 production (5–11). And reciprocally,
mice overexpressing an IL-4 transgene in T cells developed
allergic-like disorders of the eye, skin, and/or lung (12). Ad-
ditionally, in humans, overproduction of IL-4 is associated
with allergic diseases. Another important IL-4–mediated ef-
fect is to downregulate inflammatory responses which, left
unchecked, may lead to tissue damage and chronic inflam-
matory disorders (for a review, see reference 13).
Expression of the IL-4 gene is tightly regulated. IL-4
production is limited to a subset of lymphoid cells: Th2
cells, NK T cells, Tc2 CD8
 
 
 
 cells, mast cells and basophils,
eosinophils, and possibly 
 
 
 
/
 
 
 
 T cells (for a review, see ref-
erence 14). Moreover, IL-4 gene transcription occurs in
these cell types only in response to antigen-T cell receptor
stimulation. Recent progress has been made in identifying
the transcription factors that control the expression of the
IL-4 gene in Th2 cells (for a review, see reference 15). In
vitro
 
 
 
analyses of the proximal IL-4 promoter demonstrate
that both the c-maf proto-oncogene (a member of the acti-
vating protein 1 [AP-1] family of basic region/leucine
zipper proteins) and nuclear factor of activated T cells
(NFAT)
 
*
 
 family members (NFATc1, c2, and c3 also called
NFATc, NFATp [NFAT1], and NFAT4 [NFATx], re-
spectively) transactivate the proximal IL-4 promoter. The
expression and activity of both c-maf and NFAT are regu-
lated through T cell receptor–mediated signals (16, 17). In
vivo studies substantiate an essential role for c-maf in tissue-
specific regulation of the IL-4 gene, as mice deficient for
c-maf have severely impaired production of IL-4 and serum
IgG1, whereas IL-4 levels are elevated in transgenic mice
whose T cells overproduce c-maf (18, 19). Other findings
highlight the complexity involved in regulatory control of
the IL-4 gene locus. For instance, the capability of c-maf–
deficient T cells to produce low levels of IL-4 when pro-
vided with exogenous IL-4 suggests the existence of other
factors which have the capacity to drive IL-4 production in
a tissue-specific manner (18). It may be that GATA3, an-
other Th2-specific factor, can serve this function, although
it is thought that its primary action is to control the coordi-
nate regulation of Th2 cytokines by remodeling chromatin
(20–22). Additionally, while mice lacking NFATc1 in T
cells have a decrease in IL-4 production and a selective loss
of IgE and IgG1 isotypes, supporting the notion that
NFAT is critical in potentiating IL-4 gene transcription,
mice lacking NFATc2 or doubly deficient for both
NFATc2 and NFATc3 show elevated levels of IL-4 (strik-
ingly so for the double mutant mice) (23–26).
 
 
 
Clearly,
NFAT family members play vital roles in both initiation
and termination of IL-4 gene production.
Recently we have identified a novel protein NIP45
(NFAT-interacting protein) which substantially augments
IL-4 gene transcription (27). NIP45 was initially identified
as a factor which interacts with the REL homology domain
(which is required for sequence-specific DNA binding) of
NFAT family members. We have shown that it is possible
to force endogenous IL-4 production in non-producer
cells. For example, the ectopic expression of c-maf and
NFAT in cells normally refractory to IL-4 production such
as B cells or Th1 clones allows the production of measur-
able, albeit low, amounts of IL-4. However, the addition of
NIP45, in conjunction with c-maf and NFAT, to the same
non-producing cell types now results in appreciable levels
of endogenous IL-4, levels that approximate those pro-
duced by primary Th2 cells. Indeed, this synergy was so
pronounced that cells transfected with NIP45 produced 50-
to 200-fold more IL-4 than cells that did not receive NIP45
(27). The mechanism by which NIP45 augments IL-4 pro-
duction remains unresolved. For example, although it is
clear that while NIP45 does cooperate with all NFAT fam-
ily members to enhance NFAT-driven transcription, it does
not transactivate the IL-4 promoter on its own.
In studies designed to further our understanding of
NIP45 activity we have uncovered a novel facet of IL-4
gene regulation. We present evidence that members of the
TRAF family of proteins, generally known to function as
adapter proteins that transduce signals from the TNFR su-
perfamily, may also contribute to the repression of IL-4
gene transcription and that this effect is mediated through
their interaction with NIP45.
 
Materials and Methods
 
Mice and Cell Lines.
 
TRAF2.DN transgenic mice (which
overexpress a lymphocyte-specific mutant form of TRAF2 trans-
gene such that the N-terminal RING finger domain and zinc fin-
gers are deleted) were provided by Dr. Y. Choi (The Rockefeller
University, New York, NY) (28). Age-matched wild-type
C57BL/6 mice (The Jackson Laboratory) were used as controls.
Mice were used from 12 to 16 wk of age. M12C3 (M12) is a mu-
rine B lymphoma cell line and Jurkat is a human T lymphoma
cell line. Cell lines and primary cells were maintained in com-
plete media (CM) containing RPMI 1640 supplemented with
heat-inactivated 10% fetal calf serum (Hyclone Laboratories),
glutamine (2 mM), penicillin (50 U/ml), streptomycin (50 
 
 
 
g/
ml), Hepes (100 mM), and 
 
 
 
-ME (50 
 
 
 
M).
 
Yeast Two-Hybrid Screen.
 
The full-length NIP45 cDNA was
engineered by PCR to be flanked by EcoR1 and Xho1 and
cloned inframe, N-terminal to the Lex A DNA-binding domain,
into the bait vector pEG202 to produce pEG202-NIP45. This
bait was used to screen two expression libraries: one constructed
from cDNA derived from the Th1 clone OF6 (29) and the other
from a Th2 clone D10 (16) as described (27).
 
Coimmunoprecipitation.
 
Immunoprecipitation experiments
were performed using anti-Flag and anti-MYC antibodies essen-
tially as described previously (30).
 
Th Cell Purification and In Vitro Differentiation.
 
Single cell sus-
pensions were prepared from spleen and lymph node and de-
pleted of red blood cells using RBC lysis buffer (Sigma-Aldrich)
and B cells by panning against IgG and IgM positive. CD4-posi-
tive T cells were then isolated by incubating with anti-CD4
MACS micromagnetic beads (Miltenyi Biotec) and positively se-
lecting by high-gradient magnetic cell separation using VS
 
 
 
MACS columns (Miltenyi Biotec) according to the manufac-
turer’s instructions. Naive cells were obtained by sorting (MO
 
*
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2
 
-terminal kinase; NFAT,
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FLO; Cytomation) cells that had been harvested from lymph
node and spleen, depleted of B cells, stained with FITC-conju-
gated anti-CD4 antibody and PE-conjugated Mel-14 (CD62L)
antibody, resuspended in RPMI supplemented with 1% fetal calf
serum at 10
 
7
 
 cells/ml. The CD4-, Mel-14 (CD62L) high popula-
tion were collected at 
 
 
 
98% purity. For in vitro differentiation
assays, purified naive or total CD4 cells (10
 
6
 
/ml) were stimulated
with 2 
 
 
 
g/ml plate-bound anti-CD3
 
 
 
 antibody and 2 
 
 
 
g/ml
plate-bound anti-CD28 antibody. IL-12 and anti–IL-4 were
added for Th1 differentiation and IL-4 and anti–IFN-
 
 
 
 for Th2
differentiation. On day 3, 200 U/ml of IL-2 was added to all cul-
tures. On day 8, cells were harvested, washed, and restimulated
(at 10
 
6
 
 cells/ml) with 2 
 
 
 
g/ml plate-bound anti-CD3
 
 
 
 and 2 
 
 
 
g/
ml plate-bound anti-CD28 antibody for 24 h. Culture superna-
tants were collected and levels of cytokine production were mea-
sured by ELISA.
 
Intracellular Staining.
 
Purified, naive CD4 cells were differen-
tiated in culture for 7 d and restimulated with 50 ng/ml PMA
(Sigma-Aldrich) and 1 
 
 
 
M ionomycin (Calbiochem) for 5 h with
the addition of monensin for the last 3 h of stimulation. Cells
were then fixed in 4% paraformaldehyde for 20 min, permeabi-
lized by washing in PBS supplemented with 0.1% saponin/1%
FCS, and incubated with either PE-conjugated and FITC-conju-
gated anticytokine antibodies. PE-conjugated and FITC-conju-
gated, isotype-matched monoclonal antibody controls were used
to evaluate background staining. After a final wash, cells were an-
alyzed on a FACScan™ flow cytometer (Becton Dickinson).
 
Expression Constructs, Transfections, and Luciferase Assays.
 
The
following mammalian expression vectors and reporter constructs
have been described previously: NFATC2 (referred to as
NFATp), c-maf, NIP45, TRAF1, TRAF 2, TRAF3, TRAF4,
TRAF 5, TRAF6, IL-4-luc (which contains 807 bp upstream of
the murine IL-4 promoter), Egr3-luc (which contains bases
 
 
 
2,952 to 
 
 
 
86 of the Egr3 promoter) (18, 27, 31–34). M12 or
Jurkat cells (at 5 
 
  
 
10
 
6
 
 cells in 0.4 ml of RPMI were transiently
transfected by electroporation using a Bio-Rad Laboratories elec-
troporator. In brief, DNA (quantities stated in figure legends) was
combined with cells in a 0.4 
 
 
 
M cuvette, electroporated (280 V,
975 
 
 
 
F for M12 and 270 V, 975 
 
 
 
F for Jurkat), and plated in 6
ml of complete medium. At 18 to 36 h after transfection, cells
were harvested and whole cell lysates were prepared with re-
porter lysis buffer (Promega) and used for luciferase assays. Values
were calculated as fold increase over the reporter luciferase con-
struct alone. Each transfection experiment was repeated between
four and seven times.
 
ELISA.
 
Cytokine protein levels in tissue culture supernants
were measured by ELISA essentially as described previously (23).
All anticytokine capture antibodies and anticytokine biotinylated
detection antibodies were purchased from BD PharMingen. Cal-
culated values are expressed as means 
 
  
 
SEM.
 
Western Blot Analyses.
 
Whole cell extracts or nuclear extracts
were prepared as described (4). 25 
 
 
 
g of protein was run on a
7.5% SDS-polyacrylamide gel and transferred to nitrocellulose.
The filters were probed with a combination of two separate anti-
NIP45 monoclonal antibodies, NIP451-1 and NIP454-7 of the
IgG1 isotypes, respectively. Blots were developed with horserad-
ish peroxidase (HRP)-conjugated secondary antibodies and en-
hanced chemoluminescence (ECl).
 
Results and Discussion
 
NIP45 Interacts with TRAF Family Members.
 
Previ-
ously we have shown that NIP45 can synergize with the
transcription factors NFAT and c-maf to potently upregu-
late IL-4 production. However, the mechanism by which
NIP45 augments IL-4 gene activity remains unclear. For
example, we cannot detect direct binding of NIP45 to IL-4
promoter DNA as measured by electrophoretic mobility
shift assays (unpublished data). It may be that other pro-
teins, in addition to NFAT and c-maf, are required for the
stable association of NIP45 within the context of the IL-4
transcription complex.
 
 
 
Therefore, to explore the possibility
that NIP45 may associate with other proteins in addition to
NFAT, we used the yeast two-hybrid system to search for
potential interacting partners using full-length NIP45
cDNA as “bait”. Two T cell cDNA expression libraries
were screened. One of the interacting proteins isolated was
TRAF1, a member of the TRAF family of proteins known
to function as signal transduction molecules (for a review,
see reference 34). A coimmunoprecipitation assay was used
to determine whether NIP45 and any of the six known
TRAF family members (identified in human and mouse)
could associate in vivo. cMyc-tagged NIP45 was coex-
pressed with each Flag-tagged TRAF (1 through 6) in tran-
siently transfected human embryonic kidney 293T cells.
NIP45-cMyc immunoprecipitated with anti-Flag antibody
only in the presence of flag-tagged TRAFs demonstrating
that NIP45 can form a physical association with all six
TRAF proteins (Fig. 1).
By definition, all members of the TRAF family of pro-
teins have in common a “TRAF domain” which is a
unique, highly homologous stretch of 
 
 
 
200 amino acids
positioned near the COOH terminus and is the only pre-
dicted structural domain shared by all six TRAF proteins
(35, 36). As NIP45 is able to coimmunoprecipitate with all
TRAF proteins, it was likely that this interaction was me-
diated via the TRAF domain. A series of progressive 5
 
 
 
 to
3
 
 
 
 truncation mutants of TRAF5 fused to the activation
Figure 1. Interaction of NIP45 and TRAF family members in 293
cells. Tagged expression vectors (myc-NIP45 and Flag-TRAF1 through
6) were transfected into 293 cells. Whole cell lysates were prepared for
immunoprecipitation with an antibody to Flag (top and middle panels).
Western blot analysis was done with an antibody to myc (top panel) or
Flag (middle panel). To evaluate the amount of myc-NIP45 protein pro-
duced, lysates were analyzed by Western blotting with an antibody to
myc (bottom panel). 
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domain of GAL4 were tested for their ability to interact
with NIP45 in yeast. In fact, expression of just the TRAF
domain was sufficient to promote interaction with NIP45
(data not shown). However, because all of the mutants
evaluated retained the TRAF domain, we cannot rule out
the possibility that NIP45 can also interact with other re-
gions of the TRAF proteins.
 
TRAF2 Represses Both IL-4 Promoter Transactivation and
Production of Endogenous IL-4.
 
To directly assess whether
TRAFs can exert an effect on IL-4 promoter transactiva-
tion, M12 or Jurkat cells were transiently cotransfected
with combinations of plasmids expressing c-maf, NFATc2,
NIP45, and TRAF family members (TRAF1 through 6)
in conjunction with an IL-4 promoter reporter construct
(Fig. 2 A). NIP45 typically functions to enhance c-maf/
NFATc2-driven transactivation of the IL-4 promoter. The
provision of TRAF2 in addition to NIP45 resulted in
marked repression of c-maf/NFATc2-driven transactiva-
tion of the IL-4 promoter. TRAF1 and TRAF4 were also
found to significantly inhibit IL-4 promoter transactivation.
TRAF1, 2, and 4 differ in their tissue distribution (34).
TRAF1 has been identified in spleen, lung, and testis,
Figure 2. TRAF2 inhibits IL-4 promoter transactivation. (A) TRAF1, TRAF2, and
TRAF4, but not TRAF3, TRAF5, and TRAF6, decrease NIP45/NFAT/c-maf-driven
transactivation of the IL-4 promoter. M12 or Jurkat cells were transfected with the IL-4-luc
reporter vector (5  g) and expression vectors for c-maf (5  g), NFATc2 (NFATp) (5  g),
NIP45 (10  g), and TRAF1 or TRAF2 orTRAF3 or TRAF4 or TRAF5 or TRAF6 (5
 g), or pCI vector control (between 10 to 20  g) in various combinations as indicated. 18
to 36 h after transfection, total cell lysate was prepared and luciferase activity was assayed as
described in Materials and Methods. Shown is luciferase activity relative to the control
vector. (B) TRAF2 potently represses NIP45/NFAT/c-maf potentiated transactivation of
the IL-4 promoter. (C) TRAF2-mediated repression of IL-4 promoter activity requires
NIP45. For B and C, M12 or Jurkat cells were transiently cotransfected with the IL-4-luc
reporter construct and expression vectors and measured for subsequent luciferase activity
as described in panel A except expression vector for TRAF2 was used at 10  g per trans-
fection. (D) TRAF2 does not affect NFAT/NIP45-driven transactivation of the Egr3 pro-
moter. M12 or Jurkat cells were transiently cotransfected with the Egr3-luc reporter vec-
tor (5  g) and expression vectors for NFATc2 (5  g), NIP45 (10  g), and either TRAF2
(10  g) or pCI vector control (10  g), and assayed for luciferase activity as described in
panel A. (All results presented are representative of three to six independent experiments.) 
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whereas TRAF2 appears to be ubiquitously expressed.
TRAF4 is highly expressed during embryogenesis and in
regions of the adult brain. Thus, the tissue distribution of
TRAF1 and TRAF2 is compatible with a potential role in
IL-4 gene regulation. To interpret these findings we
needed to address the following points: (a) is this TRAF
mediated repression of IL-4 promoter activity dependent
on NIP45? (b) Is this TRAF-mediated repression specific
to the IL-4 promoter?
To address these issues we performed the following ex-
periments using TRAF2 which repeatedly led to the great-
est inhibition of c-maf/NFATc2-driven transactivation of
the IL-4 promoter (Fig. 2 B). First, the promoter transacti-
vation assays were repeated in the absence of NIP45. In
these conditions, TRAF2 no longer significantly repressed
c-maf/NFATc2-driven IL-4 promoter activity, demon-
strating that TRAF2-mediated repression does require
NIP45 (Fig. 2C). The slight decrease in c-maf/NFAT-
driven transactivation that is observed upon addition of
TRAF2 may be because TRAF2 is interacting with endog-
enous NIP45 present in both M12 and Jurkat cells. In sup-
port of this interpretation, Fig. 3 shows low levels of en-
dogenous NIP45 are present in untreated M12 cells.
Second, we asked whether the effect of the TRAF2/
NIP45 interaction was selective for IL-4 transcription or
was a generalized phenomenon. NIP45 has been shown to
augment NFAT-driven transactivation of other promoters
such as the Egr3 promoter (31). As shown in Fig. 2 D,
overexpression of TRAF2 had no influence on NIP45/
NFATc2-driven transactivation of the Egr3 promoter.
These additional transfection results suggest that TRAF2-
mediated repression of IL-4 is not due to a competition be-
tween NFAT and TRAF2 for partnering with NIP45. If
that were the case, one might have predicted that all
TRAFs would have repressive activity since they all can
physically associate with NIP45 (as demonstrated by the
above described coimmunoprecipitation experiments) and
that TRAF2 would have blocked the NIP45/NFAT asso-
ciation in the context of Egr3 promoter transactivation.
Thus, overexpression of TRAF2 significantly and specifi-
cally inhibits the very potent NIP45/NFATc2/c-maf
transactivation of the IL-4 promoter.
We then sought to test possible TRAF2 effects on endog-
enous IL-4 production using a model system in which we
were able to induce IL-4 in non-producer cells such as the B
lymphoma line, M12, by transiently overexpressing the three
factors: c-maf, NFAT, NIP45. Consistent with the promoter
assays, we found that providing the cells with TRAF2 ren-
dered them unable to produce endogenous IL-4 (Fig. 4).
 
CD4 Cells from TRAF2.DN Mice Overproduce IL-4.
 
The TRAF proteins have been extensively characterized as
a family of cytoplasmic adapter proteins which are recruited
to numerous ligand-bound receptors within the TNF re-
ceptor family such as CD27, CD30, CD40, LMP-1, IL-1,
TNFR1, and TNFR2 (34). As signaling via these receptors
has not been shown to influence IL-4 gene transcription,
we thought it important to determine whether there is in-
deed a biological role for TRAF molecules in IL-4 gene
activity. To address this issue we sought to look for pertur-
bations in IL-4 production in mice harboring a mutation in
TRAF2. We initially chose to examine mice expressing a
Figure 3. Relative comparison of levels of en-
dogenous and overexpressed NIP45 protein. Ly-
sates prepared from M12 cells transiently trans-
fected with myc-tagged NIP45 or vector only
expression plasmids were immunoblotted and
probed with a combination of two anti-NIP45
monoclonal antibodies.
Figure 4. Overexpression of TRAF2 blocks the ability of c-maf,
NFAT, and NIP45 to initiate endogenous IL-4 production. M12 murine
B lymphoma cells or Jurkat human T lymphoma cells were transiently
cotransfected with expression plasmids for c-maf (5  g), and NFATc2
(5  g), together with either NIP45 (10  g), and TRAF2 (10  g), or
pCI vector control (between 10 to 20  g) as indicated. The concentra-
tion of IL-4 in supernatants harvested 72 h after transfection was mea-
sured by ELISA as described in reference 27 (Similar results were ob-
tained in three additional independent experiments).
Figure 5. NIP45 associates with
TRAF2. Lysates prepared from Bjab
cells (human B cells) were immunopre-
cipitated with a combination of two anti
NIP45 monoclonal antibodies (accord-
ing to the methods used in reference 47).
Western blot analysis was performed
using an anti-TRAF2 antibody (Santa
Cruz Biotechnology, Inc.). IC, isotype
control; IP, immunoprecipitation. 
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TRAF2 dominant negative transgene (TRAF2.DN) (28).
Unlike TRAF2-deficient mice which are postnatal lethal,
T lymphocyte development appears to occur normally in
TRAF2.DN mice which have typical ratios of CD4
 
 
 
 to
CD8
 
 
 
 T cells in the thymus and lymph nodes (37, 38). Ad-
ditional rational to perform these experiments came from
our observations of in vivo associations of (a) endogenous
TRAF2 and endogenous NIP45 protein (Fig. 5) and (b)
overexpressed myc-tagged NIP45 and overexpressed TRAF2
dominant negative mutant protein (Fig. 6).
An important physiological consequence of IL-4 pro-
duction is to direct developing naive CD4
 
 
 
 T cells toward
a Th2 phenotype—that is a subset of CD4
 
 
 
 T cells which
secrete IL-4, IL-5, IL-10, IL-13, but not IFN-
 
 
 
 or TNF
 
 
 
.
An in vitro differentiation assay was therefore used to ex-
amine Th2 development in TRAF2.DN mice. CD4
 
 
 
 Th
cells were primed with immobilized anti-CD3/CD28
mAbs in the presence of either Th1, or Th2-polarizing
conditions, or nonskewing conditions. After 8 d of culture,
cells were rested and then restimulated with anti-CD3/
CD28 mAb. 24 h after secondary stimulation, culture su-
pernatants were collected and the levels of various cyto-
kines were determined by ELISA (Fig. 7). The most dra-
matic results were observed in the nonskewing conditions.
Between 300 and 2,500 pg/ml of IL-4 was detected in su-
pernatants from TRAF2.DN cells contrasted with superna-
tants from wild-type cells in which virtually no IL-4 was
detected. Similar increases in IL-5 and IL-13 production
was observed in the nonskewing conditions (data not
shown). Under Th2-polarizing conditions, IL-4, IL-5, and
IL-13 levels were also each elevated relative to wild-type
levels (Fig. 7). In contrast, levels of the Th1-type cytokine,
IFN-
 
 
 
, were nearly equivalent between TRAF2.DN and
wild-type control mice. It is interesting to note that in the
original characterization of the TRAF2.DN mice, TCR-
induced T cell proliferation was substantially reduced com-
pared with wild-type controls. This suggests that the
marked increase in Th2-like cytokines is not secondary to a
lymphoproliferative disorder as has been noted in several
mouse mutants (i.e., NFATc2/c3-deficient mice, CTLA4-
deficient mice)
 
 
 
(25, 39, 40). TRAF2.DN mice do display
lymphadenopathy but this has been attributed to a massive
increase in the number of CD3
 
 
 
B220
 
 
 
 B cells (28).
As CD4 cells are a mixed population of memory, naive,
and activated T helper cells we could not rule out the for-
mal possibility that overproduction of IL-4 was a secondary
consequence of a proliferative or activation defect. There-
fore, parallel experiments were performed using highly pu-
Figure 6. NIP45 associates with TRAF2 dominant negative mutant
protein in 293 cells. Myc-tagged NIP45 and either TRAF2 or
TRAF2.DN expression plasmids were transiently transfected into 293
cells. Whole cell lysates were prepared for immunoprecipitation with an
antibody to myc. Western blot analysis was done using antibodies to
TRAF2 (Santa Cruz Biotechnology, Inc.) (top panel) or myc (bottom
panel). IC, isotype control; IP, immunoprecipitation.
Figure 7. TRAF2.DN T cells have en-
hanced production of Th2 type cytokines.
CD  T cells were magnetically-purified from
spleen and lymph nodes differentiated in
vitro under nonskewing, or Th1-, or Th2-
skewing conditions as described in Materials
and Methods. Supernants from cultured cells
were harvested 24 h after secondary stimula-
tion with plate bound anti-CD3  and levels
of IL-4, IL-5, IL-13, and IFN-  were quan-
titated by ELISA. Results from two indepen-
dent experiments are represented. Two
transgenic (DN) and two wild-type (wt)
mice were analyzed per experiment. 
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rified naive CD4
 
 
 
 Thp cells isolated from spleen and
lymph nodes. Again we observed overproduction of
IL-4, IL-5, and IL-13 in the culture supernatants from
TRAF2.DN T cells which had initially been primed in
nonskewing or Th2-polarizing conditions and then reacti-
vated (Fig. 7). In addition, we found that the proliferative
responses of naive CD4
 
 
 
 Th cells from TRAF2.DN to
plate-bound anti-CD3 were normal (data not shown).
To evaluate cytokine production on a per cell basis, in-
tracellular staining was also performed (Fig. 8). Purified,
Figure 8. Th cells from
TRAF2.DN transgenic mice
produce elevated levels of IL-4
and other Th2 cytokines after in
vitro  differentiation. Naive
CD4  T cells isolated from
spleen and lymph nodes of
TRAF2.DN (DN) and wild-
type (wt) mice were differenti-
ated in vitro under nonskewing
or Th1- or Th2-skewing condi-
tions as described in Materials
and Methods. (A) Supernants
from cultured cells were har-
vested 24 h after secondary stim-
ulation with plate-bound anti-
CD3  and levels of IL-4, IL-5,
IL-13, and IFN-  were quanti-
tated by ELISA. (B) Production
of IL-4 and IFN-  (and IL-5 for
Th2-skewing conditions) cyto-
kines after restimulation with
PMA and ionomycin for 5 h was
assessed by intracellular staining
as described in Materials and
Methods. The percentage of
positive staining cells in each
gated quadrant is indicated.96 TRAF2 Inhibits IL-4 Gene Transactivation
naive CD4  T cells isolated from TRAF2.DN or wild-
type control mice underwent primary differentiation in
Th1, Th2 or nonskewing culture conditions for 7 d as de-
scribed above. Cells were then rested overnight and stimu-
lated with PMA/ionomycin and cytokine production was
measured by intracellular staining. Results from two sepa-
rate mice show that in all three of our priming culture con-
ditions (Th1, Th2, and nonskewing) there was an increase
in the percentage of TFAF2.DN-derived cells producing
IL-4 and a concomitant decrease in the percentage of IFN-
 –producing cells as compared with wild-type cells. Again,
the largest differential between TRAF2.DN and wild-type
IL-4 production was observed in the nonskewing condi-
tions. Under Th2 culture conditions a higher percentage of
TRAF2.DN cells were positive for intracellular IL-5. No
IL-5–producing cells were detected among wild-type and
TRAF2.DN cells from the Th1 or nonskewing conditions.
It is interesting to speculate that the potential increase in
IL-4 production by T cells may contribute to the over-
abundance of B cells observed in the TRAF2.DN mice.
Presently, it is an open question as to the conditions un-
der which TRAF-mediated repression of IL-4 production
might occur in vivo. An obvious possibility would be the
differential expression of TRAFs or NIP45 in Th1 but not
Th2 cell types; however, assessment of TRAF2 and NIP45
in naive and Th1 or Th2 skewed CD4  T cells gave no in-
dication of this type of tissue specificity (data not shown).
Furthermore, we did not observe differential upregulation
of NIP45 protein during in vitro differentiation of naive
CD4 cells into either Th1 or Th2 cells (Fig. 9), although it
is conceivable that the NIP45/TRAF2 interaction may
qualitatively differ in Th1 versus Th2 cells. TRAF1 and
TRAF2 have been reported to bind the cytoplasmic do-
main of CD30 which has been found to be highly ex-
pressed on human Th2 cells, although no function has yet
been attributed to this molecule in the development of
Th2 cells (41, 42). An intriguing scenario is that CD30 sig-
naling might trigger upregulation of IL-4 gene transcrip-
tion by disrupting NIP45/TRAF partnering possibly by
recruiting TRAF to the cell membrane and thus presum-
ably away from its association with NIP45. Additionally,
IL-4 has been implicated in the downregulation of inflam-
matory cytokines. Given the clear evidence of cross-regu-
lation among different cell types within the immune sys-
tem (for example during Th1/Th2 development, cytokines
produced by each subset promote same cell type develop-
ment and expansion and inhibit maturation and prolifera-
tion of the opposing cell type), one might predict that the
proinflammatory cytokines (such as TNF , and TNF 
which are ligands for TNFR1 and TNFR2) would in turn
inhibit the production of IL-4. Conceivably TRAF2-medi-
ated repression of IL-4 gene transcription might be part of
this intracellular pathway. Both of these possibilities war-
rant future investigation.
Several genetically altered mouse mutants exhibit ele-
vated levels of Th2-type cytokines. Among these are mice
lacking Jnk1/2 (c-Jun NH2-terminal kinase) which phos-
phorylates the AP-1 transcription factors that participate in
the regulation of growth signals and cytokine gene transac-
tivation. Thus, Jnk can contribute to the development of
Th2 cytokine–producing T cells (43, 44). It should be
noted that lymphocytes from TRAF2.DN mice and
TRAF2-deficient fibroblasts were defective in the TNF-
induced activation of the Jnk signal transduction pathway. It
will be important to determine whether the TRAF/NIP45-
mediated effect on IL-4 production is occurring via a direct
modification of the transcriptional machinery at the IL-4
promoter or rather through an indirect pathway such as
perturbing Jnk signaling. At present we cannot distinguish
between these two possibilities. The former is possible,
since in the TRAF overexpression studies we observed in-
hibition of IL-4 promoter transactivation and IL-4 endoge-
nous gene activity presumably in the absence of Jnk activa-
tion. On the other hand, overexpression of the dominant
negative did not have a direct effect on IL-4 expression.
What is the likelihood that endogenous NIP45 and
TRAF proteins colocalize within the cell, clearly requisite if
their physical association is to occur? Numerous studies
have classified the TRAFs as cytoplasmic adapter proteins
that interact with intracellular domains of cell surface recep-
tors and therefore must localize to the soluble fraction of the
cytoplasm of cells (for a review, see reference 34). The ex-
ception is TRAF4 which possesses a putative nuclear local-
ization signal and appears to be a predominantly nuclear
protein. Interestingly, it was recently reported that endoge-
nous TRAF2 is present in the nuclei of vascular endothelial
cells and that the N-terminal “ring finger” domain targets
TRAF2 to the nucleus (45). Additional evidence that
TRAFs may be recruited to the nucleus comes from a study
of the tissue distribution of TRAF3 which detected TRAF3
in both the nuclei of splenic B lymphocytes and a subset of
neuronal cells from the cerebellum (46). And, although
originally identified as a nuclear factor, further investigation
shows that NIP45 is also present in the cytoplasmic fraction
of lymphoid cells (unpublished data). Therefore, it is possi-
ble that NIP45 and TRAFs might interact within either the
cytoplasmic and/or nuclear compartment of the cell. Fur-
thermore, there is precedent for molecules with dual func-
tion as cytoplasmic signal transducers and as nuclear regula-
Figure 9. Upregulation of NIP45 protein during in vitro differentia-
tion of naive CD4 cells into either Th1 or Th2 cells. In vitro T cell differ-
entiation was performed as described in the Materials and Methods.
Western blot analysis was performed on whole-cell lysates prepared from
cells harvested at the indicated time points using a combination of two
anti-NIP45 monoclonal antibodies.97 Lieberson et al.
tors of gene expression such as the Stat family of proteins
and  -catenin. In addition, it was recently reported that
TRAF2 may directly participate in the transcriptional acti-
vation of the TNF target gene, E-selectin (45).
In summary, we demonstrate that TRAF2 is an interact-
ing partner of NIP45 and that a functional consequence of
the TRAF2/NIP45 association is the repression of IL-4
production due to downregulation of promoter activity.
Furthermore, we have implicated TRAF2 in IL-4 regula-
tion in vivo. These data taken together with our previous
finding that NIP45 potently augments NFAT-driven IL-4
gene transcription allows us to envision NIP45 as a modu-
lator of IL-4 gene transcription, functioning to enhance or
repress depending on whom it partners with.
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